Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01726270 · ClinicalTrials.gov registry record · Phase 2
An 8-week, Open-label, Uncontrolled Study of Tamsulosin 0.4mg in Men With Bothersome Urinary Symptoms
A Phase 2 study of Lower Urinary Tract Symptoms, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 689
- Enrollment target
- 18
- Study locations
NCT01726270: Completed Phase 2 study of Lower Urinary Tract Symptoms, sponsored by Boehringer Ingelheim.
NCT01726270 is a Phase 2 study of Lower Urinary Tract Symptoms that has completed, run by Boehringer Ingelheim. The registered enrollment target is 689 participants, roughly in line with the 718-participant average among 21 other Lower Urinary Tract Symptoms trials with a reported enrollment target. The trial reports 18 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01726270, a Phase 2 study of Lower Urinary Tract Symptoms, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 689 participants
- Enrollment target
- 18
- Study locations
Study Summary
Multicenter trial conducted in Pharmacy retail centers
Primary Outcome
Includes subjects who reported: 1. No improvement in urinary symptoms and stopped taking product, 2. Reported worsening of urinary symptoms and stopped taking the product, 3. Reported a new urinary symptom and stopped taking the product, 4. Reported no "Stop Use" condition and never took more than 1 capsule on any given day, 5. Reported a "Stop Use" condition and contacted a provider.
Conditions Studied
Interventions
- DRUG tamsulosin
Study Locations (18)
Minnesota
- Boehringer Ingelheim Investigational Site - Anoka
- Boehringer Ingelheim Investigational Site - Elk River
- Boehringer Ingelheim Investigational Site - Fridley
- Boehringer Ingelheim Investigational Site - Roseville
- Boehringer Ingelheim Investigational Site - Saint Francis
Utah
- Boehringer Ingelheim Investigational Site - Bountiful
- Boehringer Ingelheim Investigational Site - Layton
- Boehringer Ingelheim Investigational Site - Salt Lake City
- Boehringer Ingelheim Investigational Site - Syracuse
California
- Boehringer Ingelheim Investigational Site - Encino
- Boehringer Ingelheim Investigational Site - Garden Grove
- Boehringer Ingelheim Investigational Site - La Habra
Texas
- Boehringer Ingelheim Investigational Site - Longview
- Boehringer Ingelheim Investigational Site - Tyler
Alabama
- Boehringer Ingelheim Investigational Site - Hoover
Arizona
- Boehringer Ingelheim Investigational Site - Mesa
New Mexico
- Boehringer Ingelheim Investigational Site - Albuquerque
Virginia
- Boehringer Ingelheim Investigational Site - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 689 participants |
| Start Date | 2012-11 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
What the finished NCT01726270 record still lists
NCT01726270 is an interventional study that assigns participants to a tested intervention. The registered 689 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 718-participant average among 21 other Lower Urinary Tract Symptoms trials with a reported enrollment target.
The record links to 1 condition, with Lower Urinary Tract Symptoms appearing as the primary indexed condition, and to 1 intervention - of which tamsulosin is the first listed.
NCT01726270 lists 18 locations in 8 states (Minnesota, Utah, California).
Frequently Asked Questions
What is clinical trial NCT01726270 about?
NCT01726270 is a clinical study titled "An 8-week, Open-label, Uncontrolled Study of Tamsulosin 0.4mg in Men With Bothersome Urinary Symptoms". Multicenter trial conducted in Pharmacy retail centers
What is the current status of trial NCT01726270?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 689 participants. The study started on 2012-11. Estimated completion is 2013-03.
What conditions does trial NCT01726270 study?
This clinical trial studies the following conditions: Lower Urinary Tract Symptoms.
What interventions are being tested in trial NCT01726270?
The interventions under investigation include: tamsulosin (DRUG).
Who is sponsoring clinical trial NCT01726270?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01726270 being conducted?
This trial has 18 study locations across Alabama, Arizona, California, Minnesota, New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lower Urinary Tract Symptoms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01726270's enrollment target sits among peer trials
689 5th of 21 higher than 17 of 21 other Lower Urinary Tract Symptoms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lower Urinary Tract Symptoms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Testing MitoQ on Lower Urinary Tract Symptoms in Older Women With Metabolic Syndrome
RECRUITING · Phase 2
-
Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction
COMPLETED · Phase 2
-
Impact of Probiotics on Urinary Symptoms in Spinal Cord Injury SCI and SB
COMPLETED · Phase 2
-
Combined Behavioral and Drug Treatment of Overactive Bladder in Men
COMPLETED · Phase 2
-
US Imaging for the Assessment of LUTS
RECRUITING
-
Preoperative Pelvic Floor Physical Therapy to Minimize Stress Urinary Incontinence After Holmium Laser Enucleation of the Prostate
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00532051 · 690 participants
Intraocular Lens Power Calculation After Laser Refractive Surgery Based on Optical Coherence Tomography
- NCT05184335 · 690 participants · Phase 3
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
- NCT07221149 · 690 participants · Phase 2
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- NCT05750654 · 688 participants · NA
Effectiveness of Small Phlebotomy Tubes in Reducing Blood Transfusions in Adult Medical Intensive Care Unit and Intermediate Care Unit Patients With Anemia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia